Cellebrite DI Ltd. SEC filings document its foreign private issuer reporting for an AI-powered digital investigative and intelligence software business. Form 6-K current reports furnish quarterly and annual results releases, GAAP financial tables incorporated by reference into Form S-8 and Form F-3 registration statements, and annual general meeting voting results under the Israeli Companies Law and the company’s articles of association.
The filing record also includes Form 20-F annual reporting, which provides the recurring public-company framework for Cellebrite’s business, financial reporting and ordinary-share governance disclosures.
Cellebrite DI Ltd. (CLBT) filed a Form 144 reporting a proposed sale of 27,166 common shares with an aggregate market value of $481,313.61. The shares represent a small fraction of the 244,469,106 shares outstanding and are scheduled for sale on or about 09/19/2025 on NASDAQ. The shares were acquired as restricted stock from the issuer on 02/14/2025, 05/14/2025, and 08/14/2025, totaling 27,166 shares. The filing also discloses a sale during the past three months of 12,878 shares on 09/11/2025 for gross proceeds of $225,743.61. The document includes the required signer representation that no undisclosed material adverse information exists.
Cellebrite DI Ltd. (CLBT) filed a Form 144 reporting a proposed sale of 27,166 common shares with an aggregate market value of $481,313.61. The shares represent a small fraction of the 244,469,106 shares outstanding and are scheduled for sale on or about 09/19/2025 on NASDAQ. The shares were acquired as restricted stock from the issuer on 02/14/2025, 05/14/2025, and 08/14/2025, totaling 27,166 shares. The filing also discloses a sale during the past three months of 12,878 shares on 09/11/2025 for gross proceeds of $225,743.61. The document includes the required signer representation that no undisclosed material adverse information exists.